Is EyePoint Pharmaceuticals, Inc. (EYPT) a Buy, Sell, or Hold?
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
$13.73 USD
-$0.55 (-3.85%)
- Volume
- 1.06M
- Average Volume
- 1.15M
- Market Capitalization
- $1.15B
- P/E Ratio
- -3.92
- Dividend Yield
- 0.00%
- Price Target
- $37.50
- Year High
- $19.11
- Year Low
- $9.40
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.66
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Jay S. Duker |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | EYPT |
| CUSIP | 30233G209 |
| CIK | 0001314102 |
| Web | https://www.eyepoint.bio |
| Phone | 617 926 5000 |
| Currency | USD |
| Employees | 214 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.10 |
| Payout Ratio | 0.00 |
| Current Ratio | 6.66 |
| Quick Ratio | 6.63 |
| Cash Ratio | 2.07 |
Sales & Book Value
| Annual Sales | $31.37M |
| Price / Sales | 151.17 |
| Cash Flow | -3.16 |
| Price / Cash Flow | -4.24 |
| Price / Book | 5.12 |
Price Target and Rating
| Average Stock Price Forecast | $37.50 |
| High Stock Price Forecast | $39.00 |
| Low Stock Price Forecast | $36.00 |
| Forecast Upside/Downside | -63.39% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 18 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-3.17 |
| Trailing P/E Ratio | -3.92 |
| PEG Ratio | 0.12 |
| P/E Growth | 0.12 |
| Net Income | $-231.96M |
| Net Margin | -3566.63% |
| Pretax Margin | -3563.62% |
| Return on Equity | -110.54% |
| Return on Assets | -94.23% |
Financials Score
| AltmanZ Score | 4.56 |
| Piotroski Score | 1.00 |
| Working Capital | 212.04M |
| Total Assets | 288.22M |
| Ebit | -262.51M |
| Market Cap | 1.2B |
| Total Liabilities | 57.74M |
Poll Results
About EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Stock
EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant containing fluocinolone acetonide, which targets chronic non-infectious uveitis impacting the posterior segment of the eye. The company also offers DEXYCU, a dexamethasone intraocular suspension, utilized to manage post-operative ocular inflammation, such as that occurring after cataract surgery. Looking ahead, EyePoint is actively developing several pipeline therapies. This includes EYP-1901, a novel, ... bioerodible tyrosine kinase inhibitor currently formulated for twice-yearly administration, which is under development for conditions like wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Additionally, YUTIQ50 is being advanced as a treatment for chronic non-infectious uveitis affecting the posterior region of the eye. To bolster its market reach and development efforts, the company maintains strategic alliances with entities such as Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. Furthermore, a commercial collaboration with ImprimisRx PA, Inc. specifically focuses on the joint promotion of DEXYCU for inflammation following ocular surgery. Incorporated in 1987, the organization was previously known as pSivida Corp. before officially rebranding as EyePoint Pharmaceuticals, Inc. in March 2018. Its corporate headquarters are situated in Watertown, Massachusetts.
EyePoint Appoints Tarek S. Hassan, M.D.
2026-07-13 07:00:00
Globally renowned retina specialist and key opinion leader to provide strategic guidance across clinical development, commercialization, and pipeline initiatives Globally renowned retina specialist and key opinion leader to provide strategic guidance across clinical development, commercialization, and pipeline initiatives
Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could
2026-06-29 04:44:00
Unlike SpaceX, ADMA Biologics is already profitable and has a clear path to doubling over the near term. EyePoint Pharmaceuticals could soon be a key player in a $15 billion global market.
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2026-06-16 07:00:00
WATERTOWN, Mass., June 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
2026-06-09 17:12:15
EyePoint, Inc. (EYPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
EyePoint Pharmaceuticals Eyes Transformative 2026 as DURAVYU Phase 3 Data Nears
2026-05-26 12:05:01
Eyepoint Pharmaceuticals NASDAQ: EYPT executives said the company remains on track to report top-line data from its Phase 3 wet age-related macular degeneration program for DURAVYU, also known as EYP-1901, beginning in August, with a second pivotal trial expected to follow about two months later.
EyePoint Announces Participation at Upcoming Investor Conferences
2026-05-19 07:00:00
WATERTOWN, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming conferences:
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2026-05-18 07:00:00
WATERTOWN, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
2026-05-14 07:00:00
– LUGANO topline data on track for mid-2026, with LUCIA readout to follow shortly after – – Continued favorable safety profile observed in masked Phase 3 DURAVYU data, consistent with four previously completed clinical trials – – All active patients in the treatment arm have reached their second DURAVYU dosing visit, with over 35% receiving a third dose – WATERTOWN, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that the independent Data Safety Monitoring Committee (DSMC) completed its third scheduled review of the Company's pivotal Phase 3 program evaluating DURAVYU for wet age-related macular degeneration (wet AMD) and recommended that both the LUGANO and LUCIA trials continue as planned with no protocol modifications.
Frequently Asked Questions
-
What is the current EyePoint Pharmaceuticals, Inc. (EYPT) stock price?
-
EyePoint Pharmaceuticals, Inc.(NASDAQ:EYPT) stock price is $13.73 in the last trading session. During the trading session, EYPT stock reached the peak price of $19.11 while $9.4 was the lowest point it dropped to. The percentage change in EYPT stock occurred in the recent session was --3.85% while the dollar amount for the price change in EYPT stock was -$-0.55.
-
EYPT's industry and sector of operation?
-
The NASDAQ listed EYPT is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of EYPT?
-
Michael Campbell | Chief Commercial Officer
George O. Elston | Executive Vice President & Chief Financial Officer
Marcia Sellos-Moura | Chief Scientific Officer
Ramiro Ribeiro | Chief Medical Officer
Jay S. Duker | President, Chief Executive Officer & Director -
How many employees does EYPT have?
-
Number of EYPT employees currently stands at 214. EYPT operates from 480 Pleasant Street, Watertown, MA 02472, US.
-
Link for EYPT official website?
-
Official Website of EYPT is: https://www.eyepoint.bio
-
How do I contact EYPT?
-
EYPT could be contacted at phone #617 926 5000 and can also be accessed through its website. EYPT operates from 480 Pleasant Street, Watertown, MA 02472, US.
-
How many shares of EYPT are traded daily?
-
The average number of EYPT shares traded daily for last 3 months was 1.15M.
-
What is the market cap of EYPT currently?
-
The market value of EYPT currently stands at $1.15B with its latest stock price at $13.73